Resverlogix (FRA:RFS) Debt-to-Equity : -0.09 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Debt-to-Equity?

Resverlogix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.19 Mil. Resverlogix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Resverlogix's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-68.29 Mil. Resverlogix's debt to equity for the quarter that ended in Dec. 2023 was -0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Resverlogix's Debt-to-Equity or its related term are showing as below:

FRA:RFS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.85 Med: -0.16 Max: -0.01
Current: -0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Resverlogix was -0.01. The lowest was -0.85. And the median was -0.16.

FRA:RFS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs FRA:RFS: -0.09

Resverlogix Debt-to-Equity Historical Data

The historical data trend for Resverlogix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Debt-to-Equity Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.07

-0.21

-0.12

-0.11

-0.09

Resverlogix Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.10	-0.11	-0.10	-0.10	-0.09

Competitive Comparison of Resverlogix's Debt-to-Equity

For the Biotechnology subindustry, Resverlogix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Resverlogix's Debt-to-Equity falls into.

Resverlogix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Resverlogix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.19	+	0)	/	-68.293
	=	-0.09

Resverlogix's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.19	+	0)	/	-68.293
	=	-0.09

Resverlogix (FRA:RFS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Resverlogix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Resverlogix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (FRA:RFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix (FRA:RFS) Headlines

No Headlines